<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228055</url>
  </required_header>
  <id_info>
    <org_study_id>1806697620-2</org_study_id>
    <nct_id>NCT04228055</nct_id>
  </id_info>
  <brief_title>Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer2 (CLIPP2)</brief_title>
  <acronym>CLIPP2</acronym>
  <official_title>Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer2 (CLIPP2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an investigator initiated clinical study. A prospective, single arm unblinded,&#xD;
      open label study will be carried out to determine the feasibility of recruitment, retention&#xD;
      and adherence of 36 prostate cancer survivors who have been on androgen deprivation therapy&#xD;
      within the last 5 years for a lifestyle modification intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION:&#xD;
&#xD;
      Androgen deprivation therapy (ADT) has been demonstrated to improve disease free and over-all&#xD;
      survival in men with prostate cancer (PCa).&#xD;
&#xD;
      ADT for PCa is associated with adverse cardio-metabolic effects such as reduced libido, hot&#xD;
      flashes, metabolic syndrome, diabetes, myocardial infarction and stroke. This reduces quality&#xD;
      of life (QoL) and potentially affects mortality.&#xD;
&#xD;
      There is paucity of data regarding comprehensive lifestyle interventions in men on ADT for&#xD;
      Pca. Existing studies used non-standardized interventions or lack data on metabolic risk&#xD;
      factors.&#xD;
&#xD;
      CLIPP is designed to address these gaps by using an intervention modelled after the Diabetes&#xD;
      Prevention Program (DPP) with an emphasis on low carbohydrate and a Keto Diet, a standardized&#xD;
      multi-component intervention with demonstrated effectiveness in reducing diabetes risk&#xD;
      factors that has been successfully adapted for multiple disease types including breast&#xD;
      cancer.&#xD;
&#xD;
      INTERVENTION:&#xD;
&#xD;
        -  24 Weeks&#xD;
&#xD;
        -  Health Coaching Weekly&#xD;
&#xD;
        -  Serum &amp; Urine Baseline, Week 12 and Week 24&#xD;
&#xD;
        -  Anthropometric Measures&#xD;
&#xD;
        -  Questionnaires&#xD;
&#xD;
        -  BMI Measurements&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pre and Post Study Model</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reach Recruiting Target</measure>
    <time_frame>6 Months</time_frame>
    <description>Recruit 36 men with prostate cancer who have been on androgen deprivation therapy within the last 5 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention of Participants</measure>
    <time_frame>6 Months</time_frame>
    <description>75% retention rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to Intervention</measure>
    <time_frame>6 Months</time_frame>
    <description>75% attendance rate throughout 24 intervention visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>6 Months</time_frame>
    <description>Unit of Measure Mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Panel</measure>
    <time_frame>6 Months</time_frame>
    <description>Unit of Measure Mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>6 Months</time_frame>
    <description>Unit of Measure %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBC</measure>
    <time_frame>6 Months</time_frame>
    <description>Unit of Measure Mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMP</measure>
    <time_frame>6 Months</time_frame>
    <description>Unit of Measure Mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Quality of Life Questionnaire</measure>
    <time_frame>6 Months</time_frame>
    <description>PROMIS Scale v 1.2 Global Health. Scale Measurements 1 to 5 1=Poor 5=Excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Quality of Life Questionnaire</measure>
    <time_frame>6 Months</time_frame>
    <description>Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Scale of Measurement 0 to 4. 0=No Problem 4=Big Problem</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory Pathways Associated with Prostate Cancer</measure>
    <time_frame>6 Months</time_frame>
    <description>Inflammation markers measured will include Interleukin-6, Interleukin 1-beta, Interleukin-8, stromal cell derived factor 1-alpha &amp; basic fibroblast growth factor.</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiogenic Pathways Associated with Prostate Cancer</measure>
    <time_frame>6 Months</time_frame>
    <description>Determine the effect of comprehensive lifestyle modification intervention on angiogenesis, markers, important mechanisms for prostate cancer progression using blood, serum and urine. Angiogenesis markers will include vascular endothelial growth factor &amp; plasma placental growth factor using Enzyme Linked Immunosorbent Assay (ELISA)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CLIPP2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 Week Lifestyle Modification Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CLIPP2</intervention_name>
    <description>Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.</description>
    <arm_group_label>CLIPP2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with prostate cancer Stage I, II or III&#xD;
&#xD;
          -  On androgen deprivation therapy with last 5 years&#xD;
&#xD;
          -  Willing to participate in a lifestyle modification program&#xD;
&#xD;
          -  Willing to modify diet and eating practices&#xD;
&#xD;
          -  Willing to participate in blood collection, urine collection and measurements&#xD;
&#xD;
          -  Minimum of 30 days since participating in another study/trial&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  40 to 80 years of age&#xD;
&#xD;
          -  BMI &gt;25%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently participating in another study or trial&#xD;
&#xD;
          -  Currently in hospice&#xD;
&#xD;
          -  Inability to walk two city blocks&#xD;
&#xD;
          -  Inability to comprehend informed consent or procedural requirements&#xD;
&#xD;
          -  Digestive Diseases (IBD, Diverticulitis, etc) that might prevent him from increasing&#xD;
             fruit and vegetable intake&#xD;
&#xD;
          -  Subjects already following an intensive lifestyle modification plan&#xD;
&#xD;
          -  BMI &lt;25%&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Algotar, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracey Smith</last_name>
    <phone>5206268038</phone>
    <email>traceysmith@email.arizona.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amit Algotar, MD, PhD, MPH</last_name>
    <phone>5206268038</phone>
    <email>algotar@email.arizona.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Smith</last_name>
      <phone>520-626-8038</phone>
      <email>traceysmith@arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracey Smith</last_name>
      <phone>520-626-8038</phone>
      <email>traceysmith@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Algotar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Carbohydrate</keyword>
  <keyword>Ketogenic</keyword>
  <keyword>Androgen Deprivation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

